{"id":45926,"date":"2012-05-30T18:25:09","date_gmt":"2012-05-30T18:25:09","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/leading-clinical-researcher-frank-vocci-joins-journal-of-addiction-medicine.php"},"modified":"2012-05-30T18:25:09","modified_gmt":"2012-05-30T18:25:09","slug":"leading-clinical-researcher-frank-vocci-joins-journal-of-addiction-medicine","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/leading-clinical-researcher-frank-vocci-joins-journal-of-addiction-medicine.php","title":{"rendered":"Leading Clinical Researcher Frank Vocci Joins Journal of Addiction Medicine"},"content":{"rendered":"<p><p>    Research key to developing quality addiction care    programs  <\/p>\n<p>    Newswise  Philadelphia, PA (May 30, 2012)  Dr. Frank Vocci    has been named as the third Co-Editor of Journal of    Addiction Medicine, the official journal of the American    Society of Addiction Medicine (ASAM). He joins Senior Editor    Dr. George F. Koob and current Co-Editors Dr. Shannon C. Miller    and Dr. Martha J. Wunsch. Dr. Vocci, PhD, is President and    Senior Research Scientist of Friends Research Institute,    Baltimore, Maryland. Dr. Vocci previously served as Director,    Division of Pharmacotherapies and Medical Consequences of Drug    Abuse, National Institute on Drug Abuse (NIDA), and Chief, Drug    Abuse Staff, Food and Drug Administration (FDA). He is    President-Elect of The College on Problems of Drug Dependence.  <\/p>\n<p>    Dr. Vocci joins Journal of Addiction Medicine at a    critical time, with the journal experiencing such recent    changes as inclusion in PubMed, a commitment to increase issue    count from four issues to six issues a year, and an addition of    electronic publication ahead of print.  <\/p>\n<p>    We are excited to welcome a leader with such stature to our    Journals editorial team. Dr. Voccis background in the    development of medications and clinical trials as well as his    interest in blending research with practice makes him ideal for    this post, stated Dr. Lori D. Karan, Treasurer and    Publications Council Chair, ASAM.  <\/p>\n<p>    Dr. Vocci has worked on cutting edge clinical research in the    areas of addiction disorders, substance abuse disorders, and    the medical consequences of drug abuse. His clinical experience    includes studying an implantable form of buprenorphine    (PROBUPHINE), evaluating the effects of depot naltrexone    (VIVITROL) on formerly opiate dependent prisoners before their    release from prison and then for six months following release,    and ensuring that the Friends Research Institutes Torrance    clinic participates in multi-center trials evaluating    treatments for methamphetamine and cocaine dependence.  <\/p>\n<p>    He has received numerous awards for his contributions to the    field of addiction medicine, including a Meritorious Executive    award from President George Bush for his management of the NIDA    medications development program, a Distinguished Service Award    from the College on Problems of Drug Dependence for his work on    the development of buprenorphine as a treatment for opiate    dependence, and the Vernelle Fox Award from the California    Society of Addiction Medicine. He also received the FeDerSerD    (Italian Addiction Society) award.  <\/p>\n<p>    Dr. Voccis research interests include developing medications    for treating nicotine and stimulant dependence and evaluating    best practices for treatment of opiate users with criminal    justice involvement. He is beginning two new projects this    year. The first is collaboration with UCLA to evaluate the    effects of buspirone on the subjective effects and craving    associated with methamphetamine. The second is a    pharmacokinetics project with a new formulation of nicotine.    The pharmacokinetics project with this new nicotine formulation    presages a smoking cessation trial.  <\/p>\n<p>    Dr. Vocci maintains a keen interest in improving the quality of    clinical trials that evaluate treatments for substance abuse    disorders. The use of adaptive clinical trial designs,    improvements in medication adherence, and discovery of markers    of sustained improvement that predict post-treatment outcomes    are three areas he believes will become more prominent in    clinical trials in substance abusing populations in the near    future.  <\/p>\n<p>    According to Drs. Koob, Miller, and Wunsch, bringing Dr. Vocci    on board as a Co-Editor will be a wonderful new direction for    the journal. Besides his prominence in the field of addiction    medicine, his vast expertise in clinical trials will help    strengthen the journals content, which is key to improving the    quality of addiction care.  <\/p>\n<p>    Journal of Addiction Medicine is the official journal of    the American Society of Addiction Medicine. It is currently in    its sixth year of publication and features peer-reviewed    articles focused on developments in addiction medicine as well    as on treatment innovations and ethical, economic, forensic,    and social topics.  <\/p>\n<\/p>\n<p>Read the rest here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.newswise.com\/articles\/view\/589730\/?sc=rsmn\" title=\"Leading Clinical Researcher Frank Vocci Joins Journal of Addiction Medicine\">Leading Clinical Researcher Frank Vocci Joins Journal of Addiction Medicine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Research key to developing quality addiction care programs Newswise Philadelphia, PA (May 30, 2012) Dr. Frank Vocci has been named as the third Co-Editor of Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). He joins Senior Editor Dr.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/leading-clinical-researcher-frank-vocci-joins-journal-of-addiction-medicine.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-45926","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/45926"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=45926"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/45926\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=45926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=45926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=45926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}